Conjugates of cysteine engineered antibodies
US10898579B2 · kind B2 · utility
2Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2016 |
| Grant date | Jan 26, 2021 |
| Priority date | — |
| Expiry date | Dec 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.